The Bergen 4-Day Treatment (B4DT) for Obsessive-Compulsive Disorder: Outcomes for Patients Treated After Initial Waiting List or Self-Help Intervention

Launes, Gunvor; Hagen, Kristen; Öst, Lars‐Göran; Solem, Stian; Hansen, Bjarne; Kvale, Gerd

doi:10.3389/fpsyg.2020.00982

Cited by 9 publications

(7 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The secondary measures also showed a significant reduction in symptoms of anxiety (GAD-7) and depression (PHQ-9) from pre-treatment to post- and follow-up. This is in line with previous findings on B4DT for PD [ 16 ] and for B4DT treatment for OCD [ 14 , 15 , 18 , 19 , 27 ]. It should also be noted that all patients completed the treatment.…”

Section: Discussionsupporting

confidence: 93%

“…The aim of this study was to examine if the promising effects from the pilot study on the B4DT for PD with or without agoraphobia is transferable to a new clinic. We hypothesized that there would be no significant differences between the current study and the previously published pilot study on B4DT for PD, based on previous studies on implementation of B4DT on OCD in new clinics [ 18 , 19 ].…”

Section: Introductionmentioning

confidence: 97%

See 1 more Smart Citation

The Bergen 4-day treatment for panic disorder: replication and implementation in a new clinic

et al. 2022

Self Cite

View full text Add to dashboard Cite

Background Bergen 4-day treatment (B4DT) is a concentrated exposure-based treatment (cET), where the patient receives concentrated, individually tailored cognitive behavioral therapy (CBT) during four consecutive days. Previous findings have indicated that B4DT could be a promising treatment for panic disorder (PD). Aim The aim of the present study was to evaluate the implementation of B4DT for panic disorder with- and without agoraphobia, at a new clinic. This is the first replication study for B4DT on panic disorder. Method Thirty consecutively recruited patients with PD were included in an open trial design. Assessment of symptoms of panic disorder were measured with Panic Disorder Severity Scale (PDSS), while symptoms of generalized anxiety were assessed by Generalized Anxiety Disorder-7 (GAD-7) and depressive symptoms by Patient Health Questionnaire (PHQ-9) pre-treatment, post-treatment and at 3-month follow-up. Treatment satisfaction was measured with Client Satisfaction Questionnaire (CSQ-8) post-treatment. Results The results showed a significant reduction in symptom severity from pre-treatment to post-treatment (d = 4.32), and at 3-month follow-up (d = 4.91). The proportion of patients classified as fulfilling the criteria for remission was 80.0% at post-treatment and 86.7% at follow up. There was a significant reduction in symptoms of depression and generalized anxiety. Treatment satisfaction was high and none of the patients dropped out. Conclusion The current study replicated the results from the original study and indicate that the treatment can be successfully implemented at new clinics. B4DT may be a promising treatment for panic disorder and comorbid symptoms of generalized anxiety and depression. Larger and more controlled studies are needed to establish the efficacy of B4DT for panic disorder.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Introductionmentioning

confidence: 97%

The Bergen 4-day treatment for panic disorder: replication and implementation in a new clinic

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…The rates of remission were 62.5, 6.3, and 0%, respectively. For the 26 patients who were treated with the B4DT after initial self-help or waiting list, 59.5% were in remission at post-treatment, 31.0% had treatment response, and 9.5% showed no change ( 23 ). At 3-month follow-up for these 26 patients, 71.4% were in remission, 19.0% had treatment response, and 9.5% showed no change.…”

Section: Resultsmentioning

confidence: 99%

“…Two patients had improved and four patients were not interested in further treatment. Therefore, a total of 42 patients eventually received the B4DT either as initial treatment or after SH or WL [see ( 23 ) for further details].…”

Section: Methodsmentioning

confidence: 99%

Does Concentrated Exposure Treatment for Obsessive-Compulsive Disorder Improve Insomnia Symptoms? Results From a Randomized Controlled Trial

et al. 2021

Self Cite

View full text Add to dashboard Cite

Insomnia is a substantial problem in patients with obsessive-compulsive disorder (OCD). There is, however, a lack of studies investigating changes in concurrent symptoms of insomnia in OCD after concentrated treatment. A recent randomized controlled trial randomized participants to the Bergen 4-day treatment (B4DT, n = 16), or 12 weeks of unguided self-help (SH, n = 16), or waitlist (WL, n = 16). Patients from the SH- and WL-group who wanted further treatment after the 12 weeks were then offered the B4DT (total of 42 patients treated with the B4DT). There were no significant differences in symptoms of insomnia between the conditions at post-treatment, but a significant moderate improvement at 3-month follow-up for patients who received the B4DT. Insomnia was not associated with OCD-treatment outcome, and change in symptoms of insomnia was mainly related to changes in depressive symptoms. The main conclusion is that concentrated exposure treatment is effective irrespective of comorbid insomnia, and that insomnia problems are moderately reduced following treatment.

show abstract

“…Patients receive individual treatment in a group setting. The B4DT demonstrated promising treatment outcomes ( 11 – 15 ). Studies investigating the long-term outcome, report a recovery rate around 70% at 1- and 4-year follow-up ( 16 , 17 ).…”

Section: Introductionmentioning

confidence: 99%

Treatment Adherence as Predictor of Outcome in Concentrated Exposure Treatment for Obsessive-Compulsive Disorder

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background: The treatment of choice for obsessive-compulsive disorder (OCD) is exposure and response prevention (EX/RP). Previous studies have demonstrated that treatment adherence predicts treatment outcome for patients with OCD, but there is little knowledge on its role in concentrated exposure treatment for OCD.Method: In the present study, 42 patients received EX/RP treatment using the Bergen 4-day format. Adherence was measured with the Exposure and Response Prevention Adherence Scale (PEAS, rated both by patients and therapists) after the second and third day. Treatment outcome (symptoms of OCD, depression, anxiety, work- and social functioning, and well-being) was assessed at 3-month follow-up.Results: At follow-up, 71.4% were in remission. High adherence was reported (mean score of 6 on a 1–7 scale). The combination of patient- and therapist rated adherence was significantly associated with treatment outcome whilst controlling for age, sex, and pre-treatment scores. Patients with higher degree of adherence reported less symptoms, higher functioning, and more well-being at follow-up.Conclusions: The results of the present study indicated that adherence in concentrated exposure treatment is significantly associated with a wide range of treatment outcomes for OCD.

show abstract

The Bergen 4-Day Treatment (B4DT) for Obsessive-Compulsive Disorder: Outcomes for Patients Treated After Initial Waiting List or Self-Help Intervention

Cited by 9 publications

References 34 publications

The Bergen 4-day treatment for panic disorder: replication and implementation in a new clinic

The Bergen 4-day treatment for panic disorder: replication and implementation in a new clinic

Does Concentrated Exposure Treatment for Obsessive-Compulsive Disorder Improve Insomnia Symptoms? Results From a Randomized Controlled Trial

Treatment Adherence as Predictor of Outcome in Concentrated Exposure Treatment for Obsessive-Compulsive Disorder

Contact Info

Product

Resources

About